European expansion Lunit expanded offices to Amsterdam and relocated European HQ from Berlin, with strong funding support and radiology AI platform deployment across dozens of Dutch hospitals, indicating readiness for further DACH/Benelux collaboration and enterprise-scale sales in Western Europe.

Radiology AI breadth Comprehensive AI suite for chest X-ray, mammography, digital breast tomosynthesis, and triage positions Lunit to pursue multi-modality radiology contracts across hospitals, imaging centers, and national screening programs.

Strategic partnerships Active collaborations with Leica Biosystems and Indica Labs to develop AI-powered computational pathology and image analysis solutions create cross-sell opportunities into pathology workflows and biomarker workflows for PD-L1 and emerging biomarkers.

Clinical validation Validation via 100+ peer-reviewed publications and real-world deployment at 3,500+ sites strengthens sales pitches for accuracy, regulatory readiness, and clinician trust, enabling easier procurement conversations with hospitals and health systems.

Financial momentum Significant revenue range and substantial funding runway, plus recent capital raise and large-scale deployments, support larger contract opportunities, enterprise licensing, and potential expansion into oncology biomarker analytics and precision medicine offerings.